Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AbbVie Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

AbbVie yıllık ortalama 5.5% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.7% annual. Gelirler growing yılda ortalama 10.7% oranında artmaktadır. AbbVie'in özkaynak karlılığı 78.4% ve net marjı 9.6%'dir.

Anahtar bilgiler

5.5%

Kazanç büyüme oranı

2.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	10.7%
Özkaynak getirisi	78.4%
Net Marj	9.6%
Sonraki Kazanç Güncellemesi	30 Oct 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

AbbVie nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NYSE:ABBV Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	55,000	5,298	13,134	7,405
31 Mar 24	54,403	5,951	12,973	7,189
31 Dec 23	54,318	4,820	12,904	7,038
30 Sep 23	55,138	6,470	12,453	6,897
30 Jun 23	56,023	8,635	12,260	6,785
31 Mar 23	56,741	7,535	12,201	6,661
31 Dec 22	58,054	11,782	12,084	6,487
30 Sep 22	57,819	13,343	12,116	6,518
30 Jun 22	57,349	12,569	11,988	6,551
31 Mar 22	56,725	12,407	11,943	6,692
31 Dec 21	56,197	11,468	11,872	6,820
30 Sep 21	55,169	7,465	11,054	6,829
30 Jun 21	53,729	6,599	10,860	6,761
31 Mar 21	50,195	5,092	10,955	6,418
31 Dec 20	45,804	4,556	9,867	6,003
30 Sep 20	40,650	7,324	9,429	5,902
30 Jun 20	36,227	6,906	8,288	5,582
31 Mar 20	34,057	8,395	6,760	5,467
31 Dec 19	33,266	7,842	6,763	5,377
30 Sep 19	32,867	3,232	6,487	5,260
30 Jun 19	32,624	4,093	6,765	5,273
31 Mar 19	32,647	5,333	6,873	5,304
31 Dec 18	32,753	5,657	7,353	5,259
30 Sep 18	32,187	7,531	6,972	5,242
30 Jun 18	30,946	6,419	6,623	5,202
31 Mar 18	29,612	6,352	6,303	5,109
31 Dec 17	28,216	5,283	6,248	5,007
30 Sep 17	27,273	6,615	5,958	4,789
30 Jun 17	26,710	6,582	5,799	4,667
31 Mar 17	26,218	6,278	5,861	4,562
31 Dec 16	25,638	5,923	5,837	4,385
30 Sep 16	25,242	6,048	5,733	4,178
30 Jun 16	24,754	5,690	5,724	4,472
31 Mar 16	23,777	5,448	5,646	4,236
31 Dec 15	22,859	5,118	5,663	4,101
30 Sep 15	21,911	2,790	6,059	3,978
30 Jun 15	20,986	2,064	6,178	3,390
31 Mar 15	20,437	1,802	6,133	3,336
31 Dec 14	19,960	1,765	6,024	3,297
30 Sep 14	19,619	3,686	5,413	3,201
30 Jun 14	19,258	4,144	5,136	3,103
31 Mar 14	19,024	4,114	5,113	2,978
31 Dec 13	18,790	4,102	5,352	2,840

Kaliteli Kazançlar: ABBV büyük bir tek seferlik zarar ile $8.9B, 30th June, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: ABBV 'nin mevcut net kar marjları (9.6%) geçen yılın (15.4%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ABBV şirketinin kazancı son 5 yılda yılda 5.5% oranında arttı.

Büyüme Hızlandırma: ABBV 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: ABBV geçtiğimiz yıl negatif kazanç büyümesine ( -38.6% ) sahipti ve bu da onu Biotechs sektör ortalamasıyla ( 0.5% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: ABBV 'nin Özsermaye Getirisi ( 78.43% ) olağanüstü olsa da, bu ölçüt yüksek borç seviyeleri nedeniyle çarpıktır.

AbbVie Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Recent updates

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

AbbVie: Dividend Discount Model Suggests Large Valuation Risks

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Why AbbVie Remains One Of My Favorite Dividend Growers

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold US$12m worth of stock

Consensus EPS estimates fall by 10%

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

AbbVie: Growth Is Still A Better Choice

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Executive Chairman notifies of intention to sell stock

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie: A Hold Again (Rating Downgrade)

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) acquired Celsius Therapeutics, Inc. for $250 million.

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie: 5 Reasons That Make A Buy Case

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AbbVie's Q1: Positive Surprise

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie: Great To Be Proven Wrong - Still Not A Buy

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin